[go: up one dir, main page]

WO1999016460A3 - Apolipoprotein e/growth factor complexes and methods of use - Google Patents

Apolipoprotein e/growth factor complexes and methods of use Download PDF

Info

Publication number
WO1999016460A3
WO1999016460A3 PCT/US1998/020591 US9820591W WO9916460A3 WO 1999016460 A3 WO1999016460 A3 WO 1999016460A3 US 9820591 W US9820591 W US 9820591W WO 9916460 A3 WO9916460 A3 WO 9916460A3
Authority
WO
WIPO (PCT)
Prior art keywords
apolipoprotein
methods
growth factor
complexes
neurotrophin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/020591
Other languages
French (fr)
Other versions
WO1999016460A2 (en
Inventor
William D Matthew
Warren J Strittmatter
Catherine R Gutman
Stephanie M Fullerton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Priority to AU96765/98A priority Critical patent/AU9676598A/en
Priority to EP98950816A priority patent/EP1019081A2/en
Priority to CA002304720A priority patent/CA2304720A1/en
Priority to JP2000513594A priority patent/JP2001518449A/en
Publication of WO1999016460A2 publication Critical patent/WO1999016460A2/en
Publication of WO1999016460A3 publication Critical patent/WO1999016460A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Provided herein are compositions comprising complexes of apolipoprotein E and nerve growth factor, neurotrophin 4 or Ω-interferon. The apolipoprotein E can be any isoform, but is preferably apolipoprotein E3. Also preferred are covalent complexes or apolipoprotein E and nerve growth factor, Ω-interferon, or neurotrophin 4. Further provided are methods of enhancing the survival of neural cells by administering a composition comprising a complex of apolipoprotein E and nerve growth factor or neurotrophin 4. Also disclosed are methods of administering compositions comprising complexes of apolipoprotein E and Ω-interferon to protect against virus infection, treat diabetes mellitus, treat bone degradation, treat blood trauma, and produce anti-tumor effects. The claimed methods can be carried out both in vitro and in vivo.
PCT/US1998/020591 1997-09-30 1998-09-29 Apolipoprotein e/growth factor complexes and methods of use Ceased WO1999016460A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU96765/98A AU9676598A (en) 1997-09-30 1998-09-29 Apolipoprotein e/growth factor complexes and methods of use
EP98950816A EP1019081A2 (en) 1997-09-30 1998-09-29 Apolipoprotein e/growth factor complexes and methods of use
CA002304720A CA2304720A1 (en) 1997-09-30 1998-09-29 Apolipoprotein e/growth factor complexes and methods of use
JP2000513594A JP2001518449A (en) 1997-09-30 1998-09-29 Apolipoprotein E / growth factor complex and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6053397P 1997-09-30 1997-09-30
US60/060,533 1997-09-30

Publications (2)

Publication Number Publication Date
WO1999016460A2 WO1999016460A2 (en) 1999-04-08
WO1999016460A3 true WO1999016460A3 (en) 1999-06-17

Family

ID=22030099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/020591 Ceased WO1999016460A2 (en) 1997-09-30 1998-09-29 Apolipoprotein e/growth factor complexes and methods of use

Country Status (5)

Country Link
EP (1) EP1019081A2 (en)
JP (1) JP2001518449A (en)
AU (1) AU9676598A (en)
CA (1) CA2304720A1 (en)
WO (1) WO1999016460A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19745950A1 (en) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Drug carrier particle for site specific drug delivery, especially to CNS
AR035016A1 (en) * 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd COMPOSITION OF AZOL PROMOTER OF PRODUCTION / SECRETION OF NEUROTROFINE, COMPOSITE PRODROGA OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THE SAME TO PREPARE THIS LAST.
US20040120925A1 (en) * 2001-03-12 2004-06-24 Masahiro Toda Remedies for nerve damages
GB0329254D0 (en) * 2003-12-17 2004-01-21 Univ Manchester Treatment of viral infections
WO2007088479A1 (en) 2006-02-02 2007-08-09 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkb antagonist
WO2017165515A1 (en) * 2016-03-23 2017-09-28 The Research Institute At Nationwide Children's Hospital Stimulation of bone growth using apolipoprotein e

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000974A1 (en) * 1983-09-01 1985-03-14 Hybritech Incorporated Antibody compositions of therapeutic agents having an extended serum half-life
US5364769A (en) * 1990-09-25 1994-11-15 Genentech, Inc. Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
WO1995005845A1 (en) * 1993-08-20 1995-03-02 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
EP0731108A1 (en) * 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
US5604202A (en) * 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985000974A1 (en) * 1983-09-01 1985-03-14 Hybritech Incorporated Antibody compositions of therapeutic agents having an extended serum half-life
US5364769A (en) * 1990-09-25 1994-11-15 Genentech, Inc. Nucleic acid encoding neurotrophic factor four (NT-4), vectors, host cells and methods of production
US5604202A (en) * 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
WO1995005845A1 (en) * 1993-08-20 1995-03-02 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
EP0731108A1 (en) * 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUTMAN C R ET AL: "Apolipoprotein E binds to and potentiates the biological activity of ciliary neurotrophic factor", JOURNAL OF NEUROSCIENCE, vol. 17, no. 16, 15 August 1997 (1997-08-15), pages 6114 - 6121, XP002086887 *
HOLTZMAN D.M.: "Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 92, 1995, pages 9480 - 9484, XP002090818 *

Also Published As

Publication number Publication date
WO1999016460A2 (en) 1999-04-08
JP2001518449A (en) 2001-10-16
CA2304720A1 (en) 1999-04-08
AU9676598A (en) 1999-04-23
EP1019081A2 (en) 2000-07-19

Similar Documents

Publication Publication Date Title
CA2186673A1 (en) The use of fatty acids in the treatment of huntington's chorea
CA2068324A1 (en) Metal-peptide compositions and methods for stimulating hair growth
HU883981D0 (en) Process for the production of medical preparations with antiviral or antibacterial effect
EP0933995B8 (en) Method of treating endothelial injury
CA2223433A1 (en) Ob protein compositions and methods
CA2145527A1 (en) Tissue protective and regenerative compositions
EP0977564A4 (en) Forskohlin for promoting lean body mass
EP1234586A3 (en) Hepatoselective pharmaceutical actives
CA2144514A1 (en) Morphogen-induced liver regeneration
DE69840909D1 (en) ANALOG OF COCAINE
CA2148795A1 (en) Compositions of oak bark extract, related synthetic compositions, and method of using same
CA2373794A1 (en) Compositions and uses of et743 for treating cancer
AU693833B2 (en) Products containing G-CSF and TNF binding protein
CA2169173A1 (en) Methods for stimulating erythropoiesis using thrombopoietin
AU7128296A (en) Pharmaceutical combination preparations containing erythropoietin and iron preparations
DE69637825D1 (en) S-NITROSOTHIOL-ENRICHED ERYTHROCYTES AND THEIR USE
WO1999016460A3 (en) Apolipoprotein e/growth factor complexes and methods of use
AU3927189A (en) N-2,3-butadienyl tri- and tetraaminoalkane derivatives
CA2259152A1 (en) Adenovirus e4 proteins for inducing cell death
UA27048C2 (en) Medicinal preparation of immunoreplacement activity the basis of cellular suspension and method for treatment of diabetes mellitus by the use of this preparation
CA2060560A1 (en) Method for insuring adequate intracellular glutathione in tissue
RU96124444A (en) BIOLOGICAL COMPOSITION FOR THE TREATMENT OF THE RAS "COLLAHIT"
WO2000065028A3 (en) TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
CA2319542A1 (en) The treatment of sexual dysfunction in certain patient groups
EP0367514A3 (en) Human leukocyte elastase inhibitors and methods for producing and using same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 96765/98

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2304720

Country of ref document: CA

Ref country code: CA

Ref document number: 2304720

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 513594

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998950816

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998950816

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998950816

Country of ref document: EP